

Amendments to the Claims

Cancel Claims 1-5, 10-13.

Add Claims 19-23.


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. – 5. (cancelled)

6. (currently amended) A compound ~~in accordance with claim 5~~ represented by formula

I:



or a pharmaceutically acceptable salt or solvate thereof wherein:

R¹ is selected from the group consisting of: H, C₁₋₁₀alkyl, Aryl, Heteroaryl and

Heterocyclyl,

said alkyl, Aryl, Heteroaryl and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

R³ is selected from the group consisting of: C₁₋₁₀alkyl and Aryl, said alkyl and Aryl being optionally substituted with one to four substituents independently selected from R⁶;

R⁴ is selected from the group consisting of: H, C₁₋₁₀alkyl, Aryl, Heteroaryl, Heterocyclyl, said alkyl, Aryl, Heteroaryl, and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

R⁵ is selected from the group consisting of: C₁₋₁₀alkyl, Aryl, Heteroaryl and Heterocyclyl, said alkyl, cycloalkyl, Aryl Heteroaryl, and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

or alternatively, R^4 and R^5 are taken together with the atoms to which they are attached and represent a ring of 5 to 8 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with one to four substituents independently selected from R^6 ;

R^6 is independently selected from the group consisting of halo, C_{1-7} alkyl, Aryl, Heteroaryl, Heterocyclyl, OR^7 , SR^7 , $S(O)_mR^8$, $S(O)_2OR^8$, $S(O)_mNR^7R^8$, NO_2 , NR^7R^8 , $O(CR^9R^{10})_nNR^7R^8$, $C(O)R^8$, CO_2R^7 , $CO_2(CR^9R^{10})_nCONR^7R^8$, $OC(O)R^8$, CN , $C(O)NR^7R^8$, $NR^7C(O)R^8$, $OC(O)NR^7R^8$, $NR^7C(O)OR^8$, $NR^7C(O)NR^8R^9$, $CR^7(NOR^8)$, $(CR^9R^{10})_n$ -Aryl, $(CR^9R^{10})_n$ -Heteroaryl, $(CR^9R^{10})_n$ -Heterocyclyl, CF_3 and OCF_3 ;

wherein m is 0, 1 or 2 and n is an integer from 1 to 7, and the alkyl, Heterocyclyl, Aryl and Heteroaryl groups and portions are optionally substituted with 1-4 substituents selected from a group independently selected from R^{11} ;

R^7 , R^9 and R^{10} are independently selected from the group consisting of: H, C_{1-7} alkyl, Aryl, $Ar-C_{1-10}$ alkyl and mono-, di- and tri- halo substituted $Ar-C_{1-10}$ alkyl,
















or one R^9 and one R^{10} are taken together with the atoms to which they are attached and any intervening atoms and represent a ring of 3 to 8 members containing 0-2 heteroatoms independently selected from O, S and N;
















R^8 is selected from the group consisting of: C_{1-10} alkyl, Aryl and C_{1-10} alkyl-Aryl; and


R^{11} is selected from the group consisting of: halo, CN, C_{1-4} alkyl, Aryl, CF_3 and OH;

wherein R^2 is selected from the table below:

R^2		

		
---	--	--

7. (currently amended) A compound in accordance with claim [[1]] 6 wherein R³ is C₁₋₁₀alkyl with 0-1 R⁶ groups attached.

8. (currently amended) A compound in accordance with claim [[1]] 6 wherein R⁴ is H or C₁₋₁₀alkyl.




9. (currently amended) A compound in accordance with claim [[1]] 6 wherein R⁵ is C₁₋₁₀alkyl having 1-2 R⁶ groups attached.
















10. – 13. (cancelled)
















14. (currently amended) A compound in accordance with claim [[5]] 6 wherein:


R¹ represents methyl;

R³ represents 3-pentyl, and R² is selected from the table below:

R ²		
		



15. (currently amended) A compound in accordance with claim [[1]] 6 selected from the group consisting of:
- N-[3-cyano-5-(3-isobutyl-1,2,4-oxadiazol-5-yl)-4-methylthien-2-yl]-2-ethylbutanamide;
N-{3-cyano-5-[3-(2,4-dichlorobenzyl)-1,2,4-oxadiazol-5-yl]-4-methylthien-2-yl}-2-ethylbutanamide;
N-[5-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-3-cyano-4-methylthien-2-yl]-2-ethylbutanamide;
N-[5-(3-benzyl-1,2,4-oxadiazol-5-yl)-3-cyano-4-methylthien-2-yl]-2-ethylbutanamide;
N-[3-cyano-4-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)thien-2-yl]-2-ethylbutanamide;
N-[3-cyano-4-methyl-5-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)thien-2-yl]-2-ethylbutanamide;
N-[3-cyano-4-methyl-5-(3-pyridin-3-yl-1,2,4-oxadiazol-5-yl)thien-2-yl]-2-ethylbutanamide;
N-[3-cyano-4-methyl-5-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)thien-2-yl]-2-ethylbutanamide;
N-{3-cyano-5-[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]-4-methylthien-2-yl}-2-ethylbutanamide;
N-(3-cyano-5-{3-[1-(2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl}-4-methylthien-2-yl)-2-ethylbutanamide;
N-{3-cyano-5-[3-(2,4-difluorobenzyl)-1,2,4-oxadiazol-5-yl]-4-methylthien-2-yl}-2-ethylbutanamide;
N-{5-[3-(2-chloro-4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-3-cyano-4-methylthien-2-yl}-2-ethylbutanamide;
N-(5-{3-[1-(2-chloro-4-fluorophenyl)cyclopentyl]-1,2,4-oxadiazol-5-yl}-3-cyano-4-methylthien-2-yl)-2-ethylbutanamide;
N-{3-cyano-5-[3-(mesitylmethyl)-1,2,4-oxadiazol-5-yl]-4-methylthien-2-yl}-2-ethylbutanamide;
N-(3-cyano-5-{3-[4-fluoro-2-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-5-yl}-4-methylthien-2-yl)-2-ethylbutanamide;


N-(5-{3-[2,4-bis(trifluoromethyl)benzyl]-1,2,4-oxadiazol-5-yl}-3-cyano-4-methylthien-2-yl)-2-ethylbutanamide;
N-[3-cyano-5-(5-isobutyl-1,3,4-oxadiazol-2-yl)-4-methylthien-2-yl]-2-ethylbutanamide;
N-[5-(4-tert-butyl-1,3-oxazol-2-yl)-3-cyano-4-methylthien-2-yl]-2-ethylbutanamide;
N-{3-cyano-5-[4-(2,4-dichlorobenzyl)-1,3-oxazol-2-yl]-4-methylthien-2-yl}-2-ethylbutanamide;
N-(3-cyano-4-methyl-5-pyridin-4-ylthien-2-yl)-2-ethylbutanamide;
N-{3-cyano-5-[(2,4-dichlorobenzyl)(3,3-dimethylbutyl)amino]-4-methylthien-2-yl}-2-ethylbutanamide;
N-{5-[benzyl(isopropyl)amino]-3-cyano-4-methylthien-2-yl}-2-ethylbutanamide;
N-{3-cyano-5-[(2,4-dichlorobenzyl)(isopropyl)amino]-4-methylthien-2-yl}-2-ethylbutanamide;
N-[3-cyano-5-(diisobutylamino)-4-methylthien-2-yl]-2-ethylbutanamide;
N-{5-[benzyl(isobutyl)amino]-3-cyano-4-methylthien-2-yl}-2-ethylbutanamide;
N-{3-cyano-5-[(2,4-dichlorobenzyl)(isobutyl)amino]-4-methylthien-2-yl}-2-ethylbutanamide;
N-{3-cyano-5-[(2,4-dichlorophenyl)(hydroxy)methyl]-4-methylthien-2-yl}-2-ethylbutanamide;
N-(3-cyano-5-{[(2,4-dichlorobenzyl)(isobutyl)amino]methyl}-4-methylthien-2-yl)-2-ethylbutanamide;
N-[3-cyano-4-methyl-5-(4-phenylpiperazin-1-yl)thien-2-yl]-2-ethylbutanamide;
tert-butyl 4-{4-cyano-5-[(2-ethylbutanoyl)amino]-3-methylthien-2-yl}piperazine-1-carboxylate;
N-[3-cyano-4-methyl-5-(4-pyridin-2-ylpiperazin-1-yl)thien-2-yl]-2-ethylbutanamide;
N-[5-(4-benzylpiperazin-1-yl)-3-cyano-4-methylthien-2-yl]-2-ethylbutanamide;
N-{3-cyano-5-[4-(2,4-dichlorobenzyl)piperazin-1-yl]-4-methylthien-2-yl}-2-ethylbutanamide;
and
N-(5-{[(4-chlorobenzyl)oxy]methyl}-3-cyano-4-methylthien-2-yl)-2-ethylbutanamide, as well as the pharmaceutically acceptable salts and solvates thereof.

16. (currently amended) A pharmaceutical composition which is comprised of a compound in accordance with claim [[1]] 19 in combination with a pharmaceutically acceptable carrier.

17. (Withdrawn - currently amended) A method of treating type 2 diabetes mellitus in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with claim [[1]] 19 in an amount that is effective to treat type 2 diabetes mellitus.

18. (Withdrawn - currently amended) A method of preventing or delaying the onset of type 2 diabetes mellitus in a mammalian patient in need thereof, comprising administering to said patient a compound in accordance with claim [[1]] 19 in an amount that is effective to prevent or delay the onset of type 2 diabetes mellitus.

19. (New) A compound represented by formula I:



or a pharmaceutically acceptable salt or solvate thereof wherein:

R¹ is selected from the group consisting of: H, C₁₋₁₀alkyl, Aryl, Heteroaryl and Heterocyclyl,

said alkyl, Aryl, Heteroaryl and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

R² represents NR⁴R⁵,

R³ is selected from the group consisting of: C₁₋₁₀alkyl and Aryl, said alkyl and Aryl being optionally substituted with one to four substituents independently selected from R⁶;

R⁴ is selected from H and C₁₋₁₀alkyl,

R⁵ is C₁₋₁₀alkyl having 1-2 R⁶ groups attached;

R⁶ is independently selected from the group consisting of halo, C₁₋₇alkyl, Aryl, Heteroaryl, Heterocyclyl, OR⁷, SR⁷, S(O)_mR⁸, S(O)₂OR⁸, S(O)_mNR⁷R⁸, NO₂, NR⁷R⁸, O(CR⁹R¹⁰)_nNR⁷R⁸, C(O)R⁸, CO₂R⁷, CO₂(CR⁹R¹⁰)_nCONR⁷R⁸, OC(O)R⁸, CN, C(O)NR⁷R⁸, NR⁷C(O)R⁸, OC(O)NR⁷R⁸, NR⁷C(O)OR⁸, NR⁷C(O)NR⁸R⁹, CR⁷(NOR⁸), (CR⁹R¹⁰)_n-Aryl, (CR⁹R¹⁰)_n-Heteroaryl, (CR⁹R¹⁰)_n-Heterocyclyl, CF₃ and OCF₃;

wherein m is 0, 1 or 2 and n is an integer from 1 to 7, and the alkyl, Heterocyclyl, Aryl and Heteroaryl groups and portions are optionally substituted with 1-4 substituents selected from a group independently selected from R¹¹;


R⁷, R⁹ and R¹⁰ are independently selected from the group consisting of: H, C₁₋₇alkyl, Aryl, Ar-C₁₋₁₀alkyl and mono-, di- and tri- halo substituted Ar-C₁₋₁₀alkyl,

or one R⁹ and one R¹⁰ are taken together with the atoms to which they are attached and any intervening atoms and represent a ring of 3 to 8 members containing 0-2 heteroatoms independently selected from O, S and N;

R⁸ is selected from the group consisting of: C₁₋₁₀ alkyl, Aryl and C₁₋₁₀alkyl-Aryl; and

R¹¹ is selected from the group consisting of: halo, CN, C₁₋₄alkyl, Aryl, CF₃ and OH.

20. (New) A compound represented by formula I:



or a pharmaceutically acceptable salt or solvate thereof wherein:

R¹ is selected from the group consisting of: H, C₁₋₁₀alkyl, Aryl, Heteroaryl and Heterocyclyl,

said alkyl, Aryl, Heteroaryl and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

R² represents C₁₋₁₀ alkyl substituted with one to two R⁶ groups;

R³ is selected from the group consisting of: C₁₋₁₀alkyl and Aryl, said alkyl and Aryl being optionally substituted with one to four substituents independently selected from R⁶;

R⁴ is selected from the group consisting of: H, C₁₋₁₀alkyl, Aryl, Heteroaryl, Heterocyclyl, said alkyl, Aryl, Heteroaryl, and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

R⁵ is selected from the group consisting of: C₁₋₁₀alkyl, Aryl, Heteroaryl and Heterocyclyl, said alkyl, cycloalkyl, Aryl Heteroaryl, and Heterocyclyl being optionally substituted with one to four substituents independently selected from R⁶;

or alternatively, R⁴ and R⁵ are taken together with the atoms to which they are attached and represent a ring of 5 to 8 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with one to four substituents independently selected from R⁶;

each R⁶ is independently selected from the group consisting of: OR⁷, Aryl, mono-halophenyl and di-halophenyl

and when R² is other than C₁₋₁₀ alkyl, R⁶ is independently selected from the group wherein m is 0, 1 or 2 and n is an integer from 1 to 7, and the alkyl, Heterocyclyl, Aryl and Heteroaryl groups and portions are optionally substituted with 1-4 substituents selected from a group independently selected from R¹¹;

R⁷, R⁹ and R¹⁰ are independently selected from the group consisting of: H, C₁₋₇alkyl, Aryl, Ar-C₁₋₁₀alkyl and mono-, di- and tri- halo substituted Ar-C₁₋₁₀alkyl,

or one R⁹ and one R¹⁰ are taken together with the atoms to which they are attached and any intervening atoms and represent a ring of 3 to 8 members containing 0-2 heteroatoms independently selected from O, S and N;

R⁸ is selected from the group consisting of: C₁₋₁₀ alkyl, Aryl and C₁₋₁₀alkyl-Aryl; and

R¹¹ is selected from the group consisting of: halo, CN, C₁₋₄alkyl, Aryl, CF₃ and OH.

21. (new) A pharmaceutical composition which is comprised of a compound in accordance with claim 20 in combination with a pharmaceutically acceptable carrier.

22. (new) A method of treating type 2 diabetes mellitus in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with claim 20 in an amount that is effective to treat type 2 diabetes mellitus.

23. (new) A method of preventing or delaying the onset of type 2 diabetes mellitus in a mammalian patient in need thereof, comprising administering to said patient a compound in accordance with claim 20 in an amount that is effective to prevent or delay the onset of type 2 diabetes mellitus.